The Johnson & Johnson Conundrum: Growth, Not Necessarily a Guarantee of Success Johnson & Johnson's latest quarterly results have left investors questioning whether the company's consistent performance justifies its valuation.
Goldman Sachs' recent addition of JNJ to its Conviction List has renewed interest in the stock, but it's worth examining what this means for investors.
JNJ's diversified portfolio of products and therapies across various healthcare segments is a key driver behind its success. The company's Innovative Medicine division reported 11. 2% sales growth to $15.